Sivaporn Gatechompol1,2, Weerakit Harnpariphan3, Ruamthip Supanan3, Gompol Suwanpimolkul4,5,6, Jiratchaya Sophonphan7, Sasiwimol Ubolyam7,4, Stephen J Kerr7,8, Anchalee Avihingsanon7,4, Kamon Kawkitinarong4,5,6. 1. HIV-NAT, Thai Red Cross AIDS Research Centre, 104 Ratchadamri Rd., Pathumwan, Bangkok, 10330, Thailand. sivaporn.k@hivnat.org. 2. Tuberculosis Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. sivaporn.k@hivnat.org. 3. Medical Correctional Institution, Bangkok and Klong Prem Central Prison, Bangkok, Thailand. 4. Tuberculosis Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 5. King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand. 6. Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 7. HIV-NAT, Thai Red Cross AIDS Research Centre, 104 Ratchadamri Rd., Pathumwan, Bangkok, 10330, Thailand. 8. Biostatistics Excellence Centre, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Abstract
BACKGROUND: Prisons are considered as major reservoirs for tuberculosis. Preventive therapy for latent TB infection (LTBI) is an adjunctive strategy to control TB. However, LTBI data in Thai prisoners is limited. This study assessed the prevalence of LTBI and feasibility of isoniazid preventive therapy (IPT). METHODS: A cross-sectional study was conducted among prisoners in Klong Prem Central Prison, Bangkok. Participants were screened for active TB by questionnaire and chest X-ray. LTBI was evaluated by Tuberculin skin test (TST) and QuantiFERON-TB Gold Plus (QFTP) among subgroup. Participants with positive TST or QFTP were considered to have LTBI. Participants with LTBI were offered IPT. RESULTS: From August 2018-November 2019, 1002 participants were analyzed. All participants were male with a median age of 38 (IQR 32-50) years. LTBI identified by either TST/QFTP was present in 466 (46.5%) participants. TST was positive in 359 (36%) participants. In the subgroup of 294 participants who had both TST and QFTP results, 181/294 (61.6%) tested positive by QFTP. Agreement between TST and QFTP was 55.1% (Kappa = 0.17). The risk factors associated with LTBI were previous incarceration (aOR 1.53, 95%CI, 1.16-2.01, p = 0.002), history of prior active TB (aOR 3.02, 95%CI, 1.74-5.24, p < 0.001) and duration of incarceration ≥10 years (aOR 1.86, 95%CI, 1.24-2.79, p = 0.003). Majority of LTBI participants (82%) agreed to take IPT. Three hundred and 56 (93%) participants completed treatment whereas 27 (7%) participants discontinued IPT due to the side effects of INH. CONCLUSION: This is the first study to evaluate the prevalence of LTBI and feasibility of IPT among Thai prisoners. LTBI prevalence in male prisoners in Thailand is high. LTBI screening and treatment should be implemented together with other preventive components.
BACKGROUND: Prisons are considered as major reservoirs for tuberculosis. Preventive therapy for latent TB infection (LTBI) is an adjunctive strategy to control TB. However, LTBI data in Thai prisoners is limited. This study assessed the prevalence of LTBI and feasibility of isoniazid preventive therapy (IPT). METHODS: A cross-sectional study was conducted among prisoners in Klong Prem Central Prison, Bangkok. Participants were screened for active TB by questionnaire and chest X-ray. LTBI was evaluated by Tuberculin skin test (TST) and QuantiFERON-TB Gold Plus (QFTP) among subgroup. Participants with positive TST or QFTP were considered to have LTBI. Participants with LTBI were offered IPT. RESULTS: From August 2018-November 2019, 1002 participants were analyzed. All participants were male with a median age of 38 (IQR 32-50) years. LTBI identified by either TST/QFTP was present in 466 (46.5%) participants. TST was positive in 359 (36%) participants. In the subgroup of 294 participants who had both TST and QFTP results, 181/294 (61.6%) tested positive by QFTP. Agreement between TST and QFTP was 55.1% (Kappa = 0.17). The risk factors associated with LTBI were previous incarceration (aOR 1.53, 95%CI, 1.16-2.01, p = 0.002), history of prior active TB (aOR 3.02, 95%CI, 1.74-5.24, p < 0.001) and duration of incarceration ≥10 years (aOR 1.86, 95%CI, 1.24-2.79, p = 0.003). Majority of LTBI participants (82%) agreed to take IPT. Three hundred and 56 (93%) participants completed treatment whereas 27 (7%) participants discontinued IPT due to the side effects of INH. CONCLUSION: This is the first study to evaluate the prevalence of LTBI and feasibility of IPT among Thai prisoners. LTBI prevalence in male prisoners in Thailand is high. LTBI screening and treatment should be implemented together with other preventive components.
Authors: Andrea da Silva Santos Carbone; Dayse Sanchez Guimarães Paião; Renata Viebrantz Enne Sgarbi; Everton Ferreira Lemos; Renato Fernando Cazanti; Marcos Massaki Ota; Alexandre Laranjeira Junior; José Victor Bortolotto Bampi; Vanessa Perreira Fayad Elias; Simone Simionatto; Ana Rita Coimbra Motta-Castro; Maurício Antonio Pompílio; Sandra Maria do Valle de Oliveira; Albert I Ko; Jason R Andrews; Julio Croda Journal: BMC Infect Dis Date: 2015-01-22 Impact factor: 3.090
Authors: Alessandro Rolim Scholze; Josilene Dália Alves; Thaís Zamboni Berra; Felipe Lima Dos Santos; Antônio Carlos Vieira Ramos; Giselle Lima de Freitas; Maria José Quina Galdino; Flávia Meneguetti Pieri; Marcos Augusto Moraes Arcoverde; Sandra Cristina Pillon; Aline Aparecida Monroe; Inês Fronteira; Dulce Gomes; Ricardo Alexandre Arcêncio Journal: BMC Public Health Date: 2022-05-17 Impact factor: 4.135